BRIC nations – Brazil, Russia, India, and China – represent 40% of the world’s population, including a growing aging population and middle class with an increasing prevalence of chronic disease. Their healthcare systems increasingly rely on prescription drugs, but they differ from most other healthcare systems because healthcare expenditures in BRIC nations have exhibited the highest revenue growth rates for pharmaceutical multinational corporations (MNCs), Big Pharma. The response of BRIC nations to Big Pharma presents contrasting cases of how governments manage the tensions posed by rising public expectations and limited resources to satisfy them. Understanding these tensions represents an emerging area of research and an important challenge for all those who work in the field of health policy and management (HPAM).
Hamdouch A, Depret MH. La Nouvelle Economie Industrielle de la Pharmacie. Paris: Elsevier; 2001:54-56.
Tannoury M, Attieh Z. The influence of emerging markets on the pharmaceutical industry. Curr Ther Res Clin Exp. 2017;86:19-22. doi:10.1016/j.curtheres.2017.04.005
Gagnon MA, Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med. 2008;5(1):e1. doi:10.1371/journal.pmed.0050001
Light DW, Lexchin JR. Pharmaceutical research and development: what do we get for all that money? BMJ. 2012;345:e4348. doi:10.1136/bmj.e4348
Fabre G. Propriété Intellectuelle, Contrefaçon et Innovation. Rouan: University of Rouan and Le Havre Press; 2009.
Naci H, Carter AW, Mossialos E. Why the drug development pipeline is not delivering better medicines. BMJ. 2015;351:h5542. doi:10.1136/bmj.h5542
Jakovljevic M, Potapchik E, Popovich L, Barik D, Getzen TE. Evolving health expenditure landscape of the BRICS nations and projections to 2025. Health Econ. 2017;26(7):844-852. doi:10.1002/hec.3406
Evolution and patterns of global health financing 1995-2014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. Lancet. 2017;389(10083):1981-2004. doi:10.1016/s0140-6736(17)30874-7
Ahmad A, Khan MU, Patel I. Drug pricing policies in one of the largest drug manufacturing nations in the world: Are affordability and access a cause for concern? J Res Pharm Pract. 2015;4(1):1-3. doi:10.4103/2279-042x.150043
Roy V, Gupta U, Agarwal AK. Cost of medicines & their affordability in private pharmacies in Delhi (India). Indian J Med Res. 2012;136(5):827-835.
Wang H, Gusmano MK, Cao Q. An evaluation of the policy on community health organizations in China: will the priority of new healthcare reform in China be a success? Health Policy. 2011;99(1):37-43. doi:10.1016/j.healthpol.2010.07.003
Fabre G. The Chinese healthcare challenge; Comment on “Shanghai rising: avoidable mortality as measured by avoidable mortality since 2000.” Int J Health Policy Manag. 2015;4(3):195-197. doi:10.15171/ijhpm.2015.36
Yip W, Hsiao W. Harnessing the privatisation of China's fragmented health-care delivery. Lancet. 2014;384(9945):805-818. doi:10.1016/s0140-6736(14)61120-x
Chitour H. Big Pharma in China—The Driving Forces behind Their Success—A Qualitative Analysis. Chinese Stud. 2013;2(4):169-177. doi:10.4236/chnstd.2013.24028
Bioassociates. Top Pharmaceutical Multinationals in China by Investment. BioMed Tracker; 2012.
Rodwin, V., Fabre, G., Ayoub, R. (2018). BRIC Health Systems and Big Pharma: A Challenge for Health Policy and Management. International Journal of Health Policy and Management, 7(3), 201-206. doi: 10.15171/ijhpm.2017.145
Victor G. Rodwin; Guilhem Fabre; Rafael F. Ayoub. "BRIC Health Systems and Big Pharma: A Challenge for Health Policy and Management". International Journal of Health Policy and Management, 7, 3, 2018, 201-206. doi: 10.15171/ijhpm.2017.145
Rodwin, V., Fabre, G., Ayoub, R. (2018). 'BRIC Health Systems and Big Pharma: A Challenge for Health Policy and Management', International Journal of Health Policy and Management, 7(3), pp. 201-206. doi: 10.15171/ijhpm.2017.145
Rodwin, V., Fabre, G., Ayoub, R. BRIC Health Systems and Big Pharma: A Challenge for Health Policy and Management. International Journal of Health Policy and Management, 2018; 7(3): 201-206. doi: 10.15171/ijhpm.2017.145